Kavukçu S, Saatci U, Ciliv G, Söylemezoğlu O, Bakkaloğlu A, Besbas N, Ozen S
Department of Paediatrics, Hacettepe University School of Medicine, Ankara, Turkey.
Int Urol Nephrol. 1993;25(6):611-5.
In this study rhEPO, 70 U/kg, was subcutaneously administered two times a week for eight weeks to twelve nondialysed patients with renal anaemia and chronic renal failure. Renal function tests, blood pressure, Hb, Hct, FENa and Na-K-ATPase enzyme activity before and after administration of rhEPO have been studied. We have searched for correlations, if any, between these parameters. After the treatment period mean Hb concentration and mean Hct values increased from 7.5 +/- 0.3 to 8.6 +/- 0.5 g/dl and from 22.5 +/- 1.2 to 26.7 +/- 1.6%, respectively (p < 0.05), whereas no significant differences between pretreatment and posttreatment Cr and CrCl values were found (p > 0.05). No changes in blood pressure were found throughout the study. While mean FENa decreased from 10.2 +/- 1.6 to 6.15 +/- 1.05% (p < 0.05), mean Na-K-ATPase enzyme activities decreased from 0.120 +/- 0.016 to 0.095 +/- 0.025 mumol Pi/h/mg protein (p > 0.05) after treatment. In conclusion, subcutaneous administration of rhEPO, at doses of 70 U/kg twice a week in nondialysed patients increased Hb and Hct values. A significant decrease of FENa was observed after rhEPO treatment and there was no correlation between Na-K-ATPase enzyme activity and FENa.
在本研究中，对12例未进行透析的肾性贫血和慢性肾衰竭患者，每周皮下注射两次重组人促红细胞生成素（rhEPO），剂量为70 U/kg，共持续8周。研究了rhEPO给药前后的肾功能测试、血压、血红蛋白（Hb）、血细胞比容（Hct）、滤过钠排泄分数（FENa）和钠钾ATP酶活性。我们探寻了这些参数之间是否存在相关性。治疗期结束后，平均Hb浓度和平均Hct值分别从7.5±0.3 g/dl增至8.6±0.5 g/dl，以及从22.5±1.2%增至26.7±1.6%（p<0.05），而治疗前和治疗后肌酐（Cr）及肌酐清除率（CrCl）值无显著差异（p>0.05）。在整个研究过程中未发现血压有变化。治疗后，平均FENa从10.2±1.6%降至6.15±1.05%（p<0.05），而平均钠钾ATP酶活性从0.120±0.016 μmol Pi/h/mg蛋白降至0.095±0.025 μmol Pi/h/mg蛋白（p>0.05）。总之，对未进行透析的患者每周两次皮下注射70 U/kg剂量的rhEPO可提高Hb和Hct值。rhEPO治疗后观察到FENa显著降低，且钠钾ATP酶活性与FENa之间无相关性。
